HDAC9 and cancer: However, at least in the seven cancer cell lines used in this study, the simultaneous inhibition of HDAC and COX activity by dual HDAC-COX inhibitors or combination treatments did not result in additive or synergistic anticancer activities, which disagrees with previous reports.